Drug General Information
Drug ID
D0Q6MY
Drug Name
Nafamostat
Synonyms
FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum
Drug Type
Small molecular drug
Indication Coronavirus Disease 2019 (COVID-19) Phase 2/3 [1]
Middle East Respiratory Syndrome (MERS) Preclinical [2]
Therapeutic Class
Antiviral Agents
Structure
Download
2D MOL

3D MOL

Formula
C19H17N5O2
InChI
1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
InChIKey
MQQNFDZXWVTQEH-UHFFFAOYSA-N
CAS Number
CAS 81525-10-2
PubChem Compound ID
PubChem Substance ID
Target
Target(s) COVID-19 spike glycoprotein (S) Target Info Inhibitor [3]
Nafamostat mesylate inhibits SARS-CoV-2 Spike protein-initiated membrane fusion.
MERS-CoV spike glycoprotein (S) Target Info Inhibitor [2]
Nafamostat serves as a potent Inhibitor of MERS-Cov by inhibiting MERS-CoV spike glycoprotein (S) protein-mediated membrane fusion.
References
1 ClinicalTrials.gov (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health.
2 Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
3 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.